15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Relay Therapeutics Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $18.00 to $31.00, a moderate spread. The average target of $25.91 sits 36% above the current $19.10. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy19%
Buy982%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Relay Therapeutics Inc.
As of Sep, 10 of 11 firms rate RLAY a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RLAY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.46 – $-0.29 · 12 analysts · +23% YoY
Next period, 12 analysts expect Relay Therapeutics Inc to earn $-0.38 a share (range $-0.46 – $-0.29), versus $-0.31 a year earlier. Full-year consensus is $-1.62, growing to $-1.64 the year after.
REVENUE · NEXT QUARTER
$7.1M
Range $0 – $27.2M · 12 analysts · +2% YoY
Revenue is expected to reach $7.1M (range $0 – $27.2M), +1.6% year-over-year. Full-year consensus is $10.5M, rising to $16.6M next year.
Top analysts covering Relay Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RLAY.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$10.00-47.6% to target
Overall win rate
55%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #26
Buy
$21.00+9.9% to target
Overall win rate
53%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #121
Buy
$12.00-37.2% to target
Overall win rate
56%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$29.00+51.8% to target
Overall win rate
41%
+ Follow
#5
John Newman
Canaccord Genuity · Rank #409
Buy
$29.00+51.8% to target
Overall win rate
30%
+ Follow
RLAY stock forecast FAQ
What is RLAY's average 12-month price target?+
The 11 analysts with a live target average $25.91 for Relay Therapeutics Inc over the next 12 months, ranging from a $31.00 high to a $18.00 low.
Is RLAY stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RLAY?+
The Street-high target is $31.00 (JP Morgan), and the Street-low is $18.00 (Oppenheimer). The average of all 11 active targets is $25.91.
How many Wall Street analysts cover RLAY?+
11 analysts have an active rating on Relay Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering RLAY?+
Among analysts who currently cover RLAY, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $10.00 target.
What is Relay Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.46 – $-0.29) across 12 analysts. Full-year EPS is projected at $-1.62, rising to $-1.64 the following year.
How much revenue is Relay Therapeutics Inc expected to report next quarter?+
Consensus revenue is $7.1M (range $0 – $27.2M). Full-year revenue is projected at $10.5M, growing to $16.6M next year.
Have analysts been upgrading or downgrading RLAY lately?+
As of Sep, 10 of 11 firms rate RLAY a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RLAY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
